EU Marketing Approval Gap Between Lilly’s Donamemab and Eisai’s Leqembi Could Narrow

 
• By Francesca Bruce
Lilly's Alzheimer's drug donamemab is up for discussion at this month's CHMP meeting
(Shutterstock)

More from Europe

More from Product Reviews